Literature DB >> 7910152

Molecular mechanisms possibly affecting WT1 function in human ovarian tumors.

A Viel1, F Giannini, E Capozzi, V Canzonieri, C Scarabelli, A Gloghini, M Boiocchi.   

Abstract

The frequent allelic deletions observed on the short arm of chromosome 11 in ovarian tumors suggest that the WT1 gene, a proposed tumor-suppressor gene located on chromosome 11p13 and expressed in the human fetal genitourinary system, may contribute to the development of ovarian neoplasms. Structural and sequence analysis of the entire coding portions of the WT1 gene did not reveal any abnormalities in the 20 ovarian tumor specimens (13 of which showed 11p13 allelic deletions) and 5 cell lines which we analyzed. These findings invalidate the hypothesis that the WT1 gene functions as a classical tumor-suppressor gene in ovarian tumorigenesis and suggest that a different recessive oncogene may be "exposed" by the observed 11p13 allelic deletions. Expression analysis showed that the WT1 gene was transcriptionally active in all the tumors tested, but considerable variations in the mRNA levels were found. This apparent variability, which should be confirmed at the cellular level in the tumor specimens, was also observed in the ovarian tumor-cell lines. Finally, WT1 expression data were evaluated in conjunction with immunohistochemical data on p53. The possible functional effects of altered WT1 mRNA expression in ovarian tumors are discussed, taking into account the potential WT1/p53 protein interaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910152     DOI: 10.1002/ijc.2910570413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

Authors:  K M Amin; L A Litzky; W R Smythe; A M Mooney; J M Morris; D J Mews; H I Pass; C Kari; U Rodeck; F J Rauscher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

3.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 4.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Cancer immunotherapy targeting WT1 protein.

Authors:  Haruo Sugiyama
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  FGFR1 and WT1 are markers of human prostate cancer progression.

Authors:  Elizabeth Devilard; Franck Bladou; Olivier Ramuz; Gilles Karsenty; Jean-Philippe Dalès; Gwenaëlle Gravis; Catherine Nguyen; François Bertucci; Luc Xerri; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2006-11-30       Impact factor: 4.430

Review 7.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

8.  Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas.

Authors:  A Viel; L Dall'Agnese; F Simone; V Canzonieri; E Capozzi; M C Visentin; R Valle; M Boiocchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.

Authors:  H Gabra; L Taylor; B B Cohen; A Lessels; D M Eccles; R C Leonard; J F Smyth; C M Steel
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.